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Introduction: The recent advent of smartphone-linked wearable accelerometers offers a 
novel opportunity to promote physical activity using mobile health (mHealth) technology. 
 
Methods: mActive was a 5-week, blinded, sequentially-randomized, parallel group, pilot trial 
that enrolled patients at an academic preventive cardiovascular center in Baltimore, Maryland 
from 1/17/14-5/20/14. Eligible patients were 18-69 year old smartphone users who 
reported low leisure-time activity by a standardized questionnaire. After establishing baseline 
activity during a 1-week blinded run-in, we randomized patients 2:1 to unblinded or blinded 
tracking in phase I (2 weeks), then randomized unblinded patients 1:1 to receive or not 
receive smart texts in phase II (2 weeks). Smart texts provided fully-automated, personalized, 
real-time coaching 3 times/day towards a daily goal of 10,000 steps. The primary outcome 
was daily step count. 
 
Results: Forty-eight patients (22 women, 26 men) enrolled with a mean (SD) age of 58 (8) 
years, body mass index of 31 (6), and baseline daily step count of 9670 (4350). With 100% 
uptake of the intervention, the phase I change in activity was non-significantly higher in 
unblinded patients versus blinded controls by 1024 daily steps (95% CI -580-2628, p=0.21). 
In phase II, smart text receiving patients increased their daily steps over those not receiving 
texts by 2534 (1318-3750, p<0.001) and over blinded controls by 3376 (1951-4801, 
p<0.001). 
Conclusion: In present-day adult smartphone users receiving preventive cardiovascular care 
in the United States, a technologically-integrated mHealth strategy combining digital tracking 
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with fully-automated, personalized, real-time text message coaching resulted in a large 
increase in physical activity. 
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 For cardiovascular disease (CVD) prevention, physical activity is a central element of 
lifestyle guideline recommendations.1 Each 2,000 step/day increase in physical activity was 
associated with a ~10% relative reduction in the incidence of CVD.2 Benefits of physical 
activity may extend well beyond the cardiovascular system to prevention of cancer, diabetes, 
depression, lung and kidney disease, and other chronic diseases.3 However, with current low-
technology solutions available in the healthcare system, many adults do not meet minimum 
levels of physical activity advised by guidelines.1, 4 
 Pedometers are a possible tool for physical activity assessment and promotion that 
are relevant to a range of settings, including preventive healthcare clinics, physical 
rehabilitation programs, and employee wellness initiatives. In the workplace, the Cochrane 
Collaboration found limited and low-quality data for the effectiveness of pedometer 
interventions on physical activity and related health outcomes.5 While a meta-analysis of 
short-term clinical trials provided general support for pedometer use, the benefit was 
dependent on using a step diary and having a daily goal (e.g., 10,000 steps/day).6 It seems 
that pairing a pedometer with ways to increase self-awareness and elicit goal-oriented 
behavior may optimize their potential benefit. 
The digital revolution has broadened the definition of pedometer to include 
smartphone-linked wearable sensors. Integrating smartphone-based digital activity tracking 
in real-time with text message feedback represents a widely applicable avenue for therapeutic 
mobile health (mHealth) intervention as most Americans now own a smartphone and ~1.4 
billion people are using smartphones worldwide.7 In this context, we conducted a pilot trial 
testing the effects of fully-automated smartphone-based tracking and texting interventions 
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on physical activity. We hypothesized that the interventions would increase physical activity 
by increasing self-awareness of activity and eliciting goal-directed behavior through 

























The mActive trial protocol was registered before patient enrollment at 
clinicaltrials.gov (NCT01917812) and was approved by the Johns Hopkins School of 
Medicine Institutional Review Board (full protocol included with submission). This pilot trial 
was a single-center, blinded, randomized, parallel group, mHealth trial lasting 5 weeks, 
including a 1-week blinded run-in to establish adherence and baseline activity, followed by 
sequential randomization to fully-automated smartphone-based tracking and texting 
interventions in phase I (2 weeks) and phase II (2 weeks). In phase I, we randomized 
patients in a 2:1 ratio to unblinded digital physical activity tracking or continued blinded 
tracking. In phase II, we randomized unblinded patients in a 1:1 ratio to receive or not 
receive texts. All patients continued to receive routine care and gave written informed 
consent. Patients were advised of the different groups being compared. There were no 
important changes to methods after trial commencement. After enrollment, further face-to-
face visits were not routinely part of the interventions or assessments, but were offered for 
replacement of a lost device. 
 
Patients 
We enrolled patients at the Johns Hopkins Ciccarone Center for the Prevention of 
Heart Disease in Baltimore, Maryland, USA from January 17th to May 20th, 2014. We 
included patients aged 18-69 years who were users of a Fitbug-compatible smartphone (i.e., 
iPhone 4S or newer, Galaxy S3 or newer). We excluded patients who were already using an 
activity tracker, had a preferred form of activity such as swimming that was not measurable 
by the tracker, and those who were prohibited from normal activity due to reliance on a 
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cane/walker, activity-limiting osteoarthritis, pregnancy, or other condition. As we anticipated 
interventions to predominantly modify leisure-time activity, we also excluded patients who 
reported ≥3 days of moderate or vigorous activity during leisure-time for ≥30 minutes/day 
by the long form of the International Physical Activity Questionnaire (IPAQ).8 This 
standardized questionnaire is validated up to 69 years of age, which served as the rationale 
for the upper age limit in the trial. We did not have an eligibility restriction based on 
smartphone or Internet literacy, although all subjects confirmed having access to e-mail for 
pertinent trial communication. 
Baseline characteristics of participants were obtained by a combination of patient 
self-report and medical chart review. Patients reported whether or not they owned a dog, 
their marital status, and employment including the type of work if they were employed. In 
addition, patient responses to the long form of the IPAQ were used to categorize them as 
having low, moderate, or high physical activity according to the IPAQ scoring protocol as 
follows: 
 Low: not meeting criteria for moderate or high physical activity. 
 Moderate: 
a) 3 or more days of vigorous-intensity activity of at least 20 minutes per day 
OR 
b) 5 or more days of moderate-intensity activity and/or walking of at least 30 




c) 5 or more days of any combination of walking, moderate-intensity or vigorous 
intensity activities achieving a minimum Total physical activity of at least 600 MET-
minutes/week. 
 High: 
a) vigorous-intensity activity on at least 3 days achieving a minimum Total physical 
activity of at least 1500 MET-minutes/week 
OR 
b) 7 or more days of any combination of walking, moderate-intensity or vigorous-
intensity activities achieving a minimum Total physical activity of at least 3000 MET-
minutes/week. 
 
Additional clinical characteristics were obtained from the patient’s medical records. 
We extracted age, sex, race/ethnicity, and body mass index. We also determined whether a 
patient had known coronary heart disease and/or was an active cigarette smoker based on 
his or her problem list. In addition, we defined diabetes, hypertension, and dyslipidemia 
according to their presence or absence on the problem list or use of a medication for the 
condition (e.g., anyone prescribed a statin was classified as having dyslipidemia). Visit notes 
were reviewed to verify the information or obtain additional information. For example, the 




Patients used their personally owned smartphones. Digital physical activity tracking 
was performed using the Fitbug Orb (Chicago, IL, USA) (Plate 1), a display-free triaxial 
accelerometer with a diameter of 30 millimeters (1.2 inches, slightly larger than a quarter), 
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depth of 13 millimeters (0.5 inches), and weight of 0.3 ounces. It syncs via low-energy 
Bluetooth with one's smartphone. Fitbug Orbs were the commercially available form; a 
Johns Hopkins brand was not added. Patients were given the option to wear the device 
clipped to their clothes, in their pocket, or as a wrist band, per their preference and/or the 
recommended location for their main source of activity. The 3V lithium battery lasts about 6 
months and thus did not require charging or replacement during the trial. Patients were 
instructed to wear the device continuously throughout the trial except when showering or 
submerging in water. They could keep the device after their participation in the trial was 
completed, but were not given cash payments for participation or adherence. 
During enrollment, we installed the Fitbug app (Version 4.1.7) on the patient's 
smartphone, paired the Fitbug Orb to the smartphone, selected beacon mode for q15 
minute data transmission, selected background and hub modes to enable data transmission 
even when logged out, and then logged out of the app. We set and concealed the username 
and password; because this information was necessary to log in and view activity data. As a 
result, all patients were blinded at the time of enrollment. We strongly advised leaving the 
app running in the smartphone's background and leaving Bluetooth enabled for the duration 
of the trial. 
Regarding baseline physical activity, we pre-specified the latter four days of the 1-
week run-in as representing baseline activity. Our rationale for excluding earlier days was that 
they may be more subject to the Hawthorne effect.9 In addition to assessing baseline activity, 
the run-in was used to screen adherence with wearing the activity tracker. All those who 
enrolled met our criterion of adhering for ≥5 of 7 days, therefore no one was excluded 
during the run-in. The high level of adherence may have been partly related to automated 
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emails sent to all patients on the day of enrollment and day 3 reinforcing the importance of 
wearing the activity tracker. 
In phase I, unblinded patients could view their daily step count, activity time, and 
aerobic activity time on their smartphone screen (Plate 2). The Fitbug app also provided a 
history tab allowing review of data from prior days. The app indicated a step goal that was 
dynamic from day to day based on the amount of activity that a person attained and could 
go above 10,000 steps/day. Activity data were updated every 15 minutes if transmission 
occurred by beacon mode or were available at any time if a patient activated a manual data 
push or streaming mode. 
In phase II, 'smart' text messages were automatically sent by a preprogrammed 
algorithm to patients’ smartphones using Reify Health's system (Baltimore, MD, USA). 
'Smart' indicates that texts were not general educational or motivational messages, but rather 
were personalized coaching texts based on a patient’s real-time physical activity level, with 
content adapted to personal and clinical characteristics. Messages were written for a daily 
goal of 10,000 steps, consisting of positive reinforcement messages and also booster 
messages to motivate individuals when they were not on track to surpass their step goal. 
‘Smart’ texts were sent 3 times/day (morning, mid-day, and evening) with the exact times 
personalized to the patient based on their usual wake time, lunch time, and time returning 
home from work. Content was based on the integration of self-efficacy, motivation, and 
habit theories10, 11 with cardiovascular knowledge and clinical experience, and underwent 




On the day of enrollment, all patients completed a survey in order to personalize text 
messages (Table 1), which was later used in the 16 patients randomized to texts. Specific 
examples of texts sent during the trial are shown in Table 2. At enrollment, to identify 
future study text messages specifically as 'mActive' text messages, patients entered and 
labeled the mActive phone number in their smartphone. To promote privacy, we advised 
patients to set their phone to password protected mode.  
 
Outcomes 
 Our pre-specified primary outcome measure was the mean change in accelerometer-
measured daily (00:00:00 to 23:59:59) step count assessed from baseline (week 1) to phase I 
(weeks 2-3) and phase II (weeks 4-5). During the same time frames, using the same 
accelerometer, pre-specified secondary activity outcome measures were changes in total daily 
activity time and aerobic time. Aerobic time was defined as the time spent walking 
continuously for >10 minutes without breaking for more than a minute. An additional 
secondary outcome was satisfaction; qualitative feedback was obtained from patients upon 
trial completion through an online form and focus groups are currently being conducted. 
Once fully collected, satisfaction data will be synthesized and published. 
 
Physical Activity Data Accuracy 
 The Fitbug Orb uses proprietary, internally-tested algorithms to translate raw 
accelerometer data into step counts, activity time, and aerobic time. To promote accuracy, 
we set each patient’s individual stride length (calculated by multiplying height in inches by 
0.413) and selected stride extender to account for the longer stride length with jogging or 
running relative to walking. We conducted accuracy testing at Hopkins prior to trial 
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enrollment, which showed the Fitbug Orb to be reasonably comparable to traditional 
pedometers, including the higher-end Accusplit AH120MAG 
(n=40, median difference 162; 25th-75th -392-827 steps) and the lower-end SM-2000 (n=7, 
median difference -609 steps; 25th-75th -972-618). 
 
Sample Size 
 Previous randomized trials with a total of 24 to 58 patients have shown significant 
effects of activity tracker use.6 For this trial, we estimated that the sample size needed to 
detect at least a 2000 step difference in means was 42 patients assuming a within-patient SD 
of 2200 steps, 2-sided alpha of 0.05, and Beta of 0.8.12 Allowing for 15% attrition, our target 
enrollment was 48 patients. 
 
Randomization 
SSM and MJB decided on sex-stratified, block randomization and SSM generated 
random sequences in Stata 11.1 (College Station, TX). Allocation was concealed so it could 
not be foreseen in advance of, or during, enrollment. DIF enrolled patients who then 
entered the blinded run-in. SSM assigned patients to the phase I intervention by sending an 
email containing Fitbug login information on the first morning of week 2 to patients 
allocated to unblinding (confirmation of receipt requested). SSM assigned patients to the 
phase II intervention by selecting their account in the Reify system for smart texts beginning 
the first morning of week 4.  
 
Data Flow and Completeness 
 
With the tracker paired to patients’ smartphones, activity data continuously uploaded 
throughout the trial and synced with the texting system via linkage of the Fitbug-Reify 
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application programming interfaces. In addition to automated emails (baseline, day 3, and 
weekly thereafter) reminding patients to wear their activity tracker, targeted emails were sent 
if data did not upload for three consecutive days. The reason for data not uploading tended 
to be an issue with Bluetooth connectivity between the Fitbug and smartphone. DIF emailed 
20 (42%) patients and provided troubleshooting support to ensure data transmission 
(especially for the blinded group). In addition, a total of 5 (~10%) patients lost their 
accelerometer and required a replacement; one patient required 2 replacements. With these 
efforts, activity data completeness throughout the study, calculated by dividing the number 




Baseline characteristics were summarized using descriptive statistics – frequency 
(percentage) for categorical data and mean (standard deviation) for continuous data. All 
outcomes were compared between treatment arms by intention-to-treat. We did not conduct 
any interim analyses or have early stopping rules. We used Student's t test for mean 
comparison tests and calculated 95% confidence intervals. For comparisons of proportions, 
due to small cell sizes, we used Fisher’s exact test. Given the very high level of data 
completeness, we did not impute data. We did not pre-specify any subgroup analyses. 
Statistical analyses were performed using Stata version 11.1 (College Station, TX) by the 
academic investigators independently from industry. SSM and MJB had full access to all of 
the data in the study and take responsibility for the integrity of the data and the accuracy of 
the data analysis. For reporting, we followed the Consolidated Standards of Reporting Trials 






 The trial flow diagram is shown in Figure 1. Of 50 eligible individuals, 48 (96%) 
enrolled. There was 100% uptake of the intervention and all patients in the intervention 
arms completed the protocol. One blinded patient had data transmission issues in phase II 
and elected not to complete the protocol. The trial was stopped because target recruitment 




Table 3 displays baseline characteristics. There were no statistically significant 
differences between groups. Overall, 22 women and 26 men participated with a mean age of 
58 (8) years. Patients were primarily Caucasian (78%) and employed (88%), mostly in US 
Census Bureau defined management and professional occupations. The mean body mass 
index was 31 (6) with 54% of patients obese. A clinical history of coronary heart disease was 
present in 29% and diabetes in 23%.  
 
Association of Self-Reported and Measured Physical Activity at Baseline 
 According to baseline self-report per the IPAQ, 10 patients (21%) were categorized 
at a low level of physical activity, 21 (44%) at a moderate level, and 17 (35%) at a high level 
(no significant differences between study arms). In these three groups, respectively, the 
measured baseline steps/day were 8745 (3428), 9184 (4373), and 10815 (4779).  There was 
not a statistically significant association between self-reported and measured physical activity 




 The baseline daily step count was 9670 (4350) in all patients, 10822 (4337) in the 
blind group and 9094 (4308) in the unblinded group (mean difference -1727, 95% CI -4389 
to 934; p=0.20). In phase I (Table 4), blinded control patients obtained a mean of 616 
fewer steps/day (6% decrease) while unblinded patients increased their steps/day by a mean 
of 408 (4% increase). The between-group differential was non-significantly higher in 
unblinded patients versus blinded controls by 1024 steps/day (95% CI -580-2628, p=0.21). 
 In phase II (Table 4), the blinded group further decreased its activity by 1042 
steps/day (11% decrease) while the unblinded-no texts group decreased by 200 steps/day 
(0% change). In contrast, the unblinded-texts group obtained 2334 more steps/day (25% 
increase). The differential in activity levels was significant; text receiving patients increased 
their daily steps over those not receiving texts by 2534 (95% CI 1318-3750, p<0.001) and 
over blinded controls by 3376 (95% CI 1951-4801, p<0.001). 
 
Secondary Outcomes 
Secondary outcomes were broadly consistent with the primary outcome. The 
baseline total activity and aerobic times were 93 (45) minutes/day and 13 (18) minutes/day, 
respectively. In phase I, the unblinded and blinded groups were not significantly different in 
modifying their total activity times, while there was a borderline significant lower decrease in 
aerobic time in unblinded patients of -3 (12) minutes vs -11 (14) minutes (differential  8 
minutes, 95% CI 0-16, p=0.05). In  phase II, activity times continued to decrease in the 
blinded group and remained relatively stable in the unblinded-no texts group. In contrast, 
the unblinded-texts group increased its total activity time by 21 (20) minutes/day (23% 
increase) and aerobic time by 13 (11) minutes/day (160% increase), increases which were 
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highly statistically significant referenced to both the unblinded-no text group and blinded 
group. 
 
10,000 Steps/Day Goal Attainment 
At baseline, 23 (48%) patients had a daily step count ≥10,000 steps/day, 9 (56%) in 
the blinded group and 14 (44%) in the unblinded group (Figure 2). In phase I, the ≥10,000 
step/day goal was attained by one fewer patient in both the blinded group (n=8 of 16, 50%) 
and in the unblinded group (n=13 of 32, 41%). In phase II, the number of patients meeting 
the 10,000 steps/day goal was 7 (44%) in both blinded group and the unblinded-no texts 
group. In contrast, 13 (81%) of patients who were unblinded and receiving texts had a daily 
step count ≥10,000 steps/day, a difference that was statistically significant compared to the 
other groups (p=0.02). 
 
Qualitative Observations 
Our research team noted that data transmission between Fitbug and Reify was not 
seamless. We observed intermittent bugs resulting in texts that were generated based on 
incorrect physical activity data. This was noted by trial patients and by SSM who used the 
system during the trial to personally monitor it. Reify was not able to create a permanent fix, 
therefore the issue affected patients throughout the trial. In addition, there was a day when a 








The most important finding from the mActive trial is that the group receiving 
activity information continuously via a smartphone-linked digital tracker together with fully-
automated, real-time, personalized smart text message coaching achieved the best physical 
activity outcomes. This pilot trial lends support to the efficacy of this novel, technologically-
integrated mHealth strategy in present-day adult smartphone users receiving preventive 
cardiovascular care in the United States. Potential advantages of the mActive trial strategy 
include reduction of attendance at in-person sessions, personalization of health coaching, 
more continuous patient contact, relatively low cost and reproducibility of the intervention, 
and scalability to larger target populations. The trial provides an initial step in addressing 
critical unanswered questions in an area of rapidly growing interest and represents a 
potentially widely applicable avenue for therapeutic intervention. 
Our methods and design appear to provide a significant advance over current 
approaches in the area of activity tracker (pedometer) use, text messaging, and physical 
activity. Recent randomized controlled trials that did not show efficacy for pedometer use in 
insurance company employees in Finland14 and adults with type 2 diabetes mellitus in 
southwest England15 employed low-technology tracking and did not offer smart texts. We 
are aware of only one other group16 providing text messages based on activity tracking. 
Unlike the system we implemented in the mActive trial, that system uses an activity tracker 
that uploads only through computer access points, not on-the-go through smartphones. We 
believe that allowing mobile activity data transmission anywhere will best support real-time, 
personalized smart messaging, and most harness the full power of these technologies in 
eliciting positive behavior change. 
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In addition to promoting physical activity, we suspect that the convenience offered 
by the truly mobile mActive design may have benefitted recruitment and retention. The trial 
met its recruitment target, enrolled 96% of eligible patients (as compared to the typical 
statistic of about 50%17), and all patients but one completed the protocol. Without 
specifically targeting recruitment of women, the mActive trial had nearly equal 
representation of men and women in comparison to the often disproportionately low 
representation of women in cardiovascular trials.17 The mActive trial recruitment experience 
supports the data-driven hypothesis17 that a trial design fostering convenience can enhance 
trial participation. Future trials are necessary to determine what aspects of the mActive trial 
can be scaled to larger and longer-term trials. 
Another major strength of mActive was the very high level of physical activity 
outcome completeness obtained using a digital approach. During the intervention phases of 
the trial, we sent automated weekly email reminders to reinforce the importance of wearing 
the activity tracker. While digital uploading occurred mostly without the trial coordinator 
contacting patients, the availability of real-time information allowed prompt attention to 
missing data. Along with quick responses to lost devices and questions, mActive achieved 
nearly complete activity outcome data without in-person visits or follow-up. In prior activity 
tracking trials that did not use a digital strategy, physical activity had to be manually recorded 
in a log by participants, and such an approach yielded ~40% missing data.2, 18, 19 As a result, 
the need arose for imputation of physical activity data.19 However, the mActive trial indicates 
that digital tracking can prevent the need for imputation, at least in the short-term. 
Regarding the use of text messaging in preventive healthcare, the Cochrane 
Collaboration has identified a knowledge gap in this area, which the mActive trial begins to 
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help address.20 As the field progresses, it will be important to distinguish the features (i.e., 
content, timing) of texts that are most efficacious. It is important to emphasize that the texts 
in mActive were not simply general educational or motivational texts. Instead, they were 
smart texts intended to deliver personalized coaching based on personal and clinical 
characteristics and a person’s real-time physical activity level. In addition, the positive 
reinforcement and booster texts were sent within the context of the healthcare system and 
aimed to leverage the doctor-patient relationship. Lifestyle improvement is a fundamental 
component of therapy in many clinical scenarios but the influence of behavioral counseling 
may be limited,21 especially in the current health care delivery model wherein clinicians tend 
to see patients for brief visits every several months or annually. Aimed to fill the gap, the 
system ran fully-automated without day-to-day involvement of the physician and represents 
a resource-efficient strategy to facilitate more continuous monitoring and feedback between 
the healthcare system and patients. Overall, our patient-centered, digital, and real-time 
methodology may be a novel step forward that could help shape the prevention clinic of the 
future.  
Physical activity is vital to cardiovascular health and a core element of wellness. 
Reported benefits include protection from congestive heart failure, ischemic heart disease, 
stroke, diabetes mellitus, obesity, hypertension, dyslipidemia, chronic obstructive pulmonary 
disease, chronic kidney disease, Alzheimer disease, anxiety or depression, and colon or lung 
cancer.3 In line with benefits to the cardiovascular system and multiple disease processes, 
greater physical activity is associated with a dose-dependent reduction in both cardiovascular 
and all-cause mortality.22, 23 Evidence supports a benefit from both exercise and non-exercise 
forms of physical activity. If sustained, the change in physical activity from tracking and 
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texting in this trial would be expected to be clinically significant. A similar increase of 2491 
steps/day was associated with significant decreases in body mass index and systolic blood 
pressure6 and over the long-term each 2,000 step/day increase in physical activity was 
associated with a ~10% relative reduction in the incidence of CVD.2 
Although we cannot confirm this, we suspect that mActive group as a whole 
increased physical activity levels above their pre-trial baselines regardless of intervention. 
The overall activity levels by steps, even at baseline, were relatively high, and remained so 
even in the blinded group at the end of the trial (mean 9163 steps/day). Interestingly, 
however, the activity level in the blinded group progressively decreased during the trial and it 
remains uncertain what true baseline activity levels were. Even in blinded patients, there may 
be important effects arising from enthusiasm and focus on activity in a patient who received 
encouragement from his or her physician to participate in an activity trial and then chose to 
participate. Significant changes in behavior may also occur from being observed (Hawthorne 
effect) and from an activity tracker serving as a reminder to engage in activity regardless of 
numeric feedback or texts. Despite high overall steps, aerobic activity levels were 
disproportionately low, and appeared most responsive to intervention. The unblinded-texts 
group had a 160% increase in aerobic time in phase II and concluded the trial with more 
than a 4-fold higher aerobic time over the blinded group. Aerobic time may warrant 
particular attention in future trials. 
 
Limitations 
 Like prior pedometer trials,6 a key limitation was the short-term follow-up in this 
analysis. To address this, we will perform long-term follow-up of mActive participants. 
Additional follow-up will allow assessment of changes in body mass index, blood pressure, 
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and other risk factors. Further trials are necessary to assess the generalizability of the trial 
results. While mActive involved adult smartphone users from a single preventive cardiology 
clinic, we are cautiously optimistic that the findings could be applicable to much broader 
populations throughout the healthcare system. Wearable technologies and smartphones are 
expected to only go down in cost and become more widely used over time. Although we 
excluded those who reported high leisure-time activity by IPAQ, given the lack of 
correlation between self-reported and directly-measured activity levels, it would be 
reasonable to eliminate this exclusion in the future or replace it with a directly measured 
activity exclusion. 
Additionally, there were two notable limitations to tracking-texting synchronization 
in mActive that can be improved upon in the future. First, texts were calibrated to the 
common clinical and scientific study goal of 10,000 steps/day, however the Fitbug app 
displayed a different goal that changed over time. We could not disable the app's goal and it 
may have created confusion among participants. Second, while the application programming 
interfaces of Fitbug and Reify were linked for the mActive trial, data transmission was not 
seamless. The blind group required more troubleshooting support than other groups to 
ensure physical activity data upload, which would bias to the null if there was any benefit 
from the added attention, or would bias away from the null if the frustration led to lower 
activity. We observed intermittent bugs in the texting system resulting in texts that were 
generated based on incorrect physical activity data. A better synchronized, seamless, and 
accurate smart text messaging system holds the potential to even further enhance physical 
activity levels and avoid frustration among users. Moreover, such a system could be more 




 In conclusion, in present-day adult smartphone users receiving preventive 
cardiovascular care in the United States, a technologically-integrated mHealth strategy 
combining digital tracking with fully-automated, personalized, real-time text message 
coaching resulted in a large short-term increase in physical activity. The mActive trial 
represents an encouraging early step in using technology to promote better health behaviors 
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Table 1: Factors in Personalization of Text Messages 
 Name  Occupation 
 Age  Name of spouse 
 Sex  Name of children 
 Physician name  Name of dog 
 Preferred activity  Local park 
 Favorite athlete  Gym 
 Cardiac risk factors  Work schedule 

















Table 2: Example Text Messages 
 
Time of Day Type of Message Context Text 
Morning Booster 
1006 steps under 
goal prior day 
 
Megan, you were pretty active 
yesterday! You got 8994 steps 
yesterday, which is close to your goal 
of 10,000! Dr. P is impressed by your 
progress. There are IMMEDIATE 
benefits to exercise: you will feel 






day; favorite athlete 
Lebron James 
 
Jon, you are on track to have a 
VERY ACTIVE day! Outstanding! 




3878 under goal of 
10,000 
 
Jane, giving someone a call tonight? 
Consider walking while you talk. 
Your exercise prescription for tonight 
is 3878 steps. 
 
 





























Age, years, mean (SD) 58 (8) 58 (8) 55 (8) 60 (7) 0.22 
Sex     1.00 
   Men 26 (54%) 9 (56%) 8 (50%) 9 (56%)  
   Women 22 (46%) 7 (44%) 8 (50%) 7 (44%)  
White race 38 (79%) 12 (75%) 12 (75%) 14 (88%) 0.60 
Dog owner 21 (44%) 9 (56%) 5 (31%) 7 (44%) 0.36 
Married 35 (73%) 13 (81%) 9 (56%) 13 (81%) 0.19 
Employed 42 (88%) 13 (81%) 15 (94%) 13 (81%) 0.67 
Management, 
professional* 
30 (63%) 9 (56%) 9 (56%) 12 (75%)  
Service 5 (10%) 2 (13%) 3 (19%) 0 (0%)  
Sales, office 5 (10%) 2 (13%) 2 (13%) 1 (6%)  
Construction, 
management 
2 (4%) 0 (0%) 1 (6%) 1 (6%)  
CHD 14 (29%) 5 (31%) 2 (13%) 7 (44%) 0.15 
Diabetes 11 (23%) 5 (31%) 2 (13%) 4 (25%) 0.44 
Smoker 1 (2%) 1 (6%) 0 (0%) 0 (0%) 1.00 
Hypertension 24 (50%) 8 (50%) 5 (31%) 11 (69%) 0.12 
Dyslipidemia 39 (81%) 14 (88%) 12 (75%) 13 (81%) 0.90 
BMI, Kg/m2, mean 
(SD) 
31 (6) 30 (5) 30 (7) 33 (7) 0.28 
   ≥30 26 (54%) 7 (44%) 9 (56%) 10 (63%)  
IPAQ     0.50 
   Low 10 (21%) 2 (12%) 3 (19%) 5 (31%)  
   Moderate 21 (44%) 7 (44%) 9 (56%) 5 (31%)  
   High 17 (35%) 7 (44%) 4 (25%) 6 (38%)  
 
CHD = coronary heart disease; BMI = body mass index; IPAQ = International Physical Activity 
Questionnaire, Long-Form (overall categorization); *per US Census Bureau definitions
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Mean Change (SD) 
 
Unblind - Blind 
 
Mean Difference (95% CI), p-value 
Steps, count/day (primary outcome) 408 (2701) -616 (2385) 1024 (-580 to 2628), p=0.21 
Activity time, minutes/day 2 (27) -6 (26) 8 (-9 to 25), p=0.33 









Texts - No Texts Texts - Blind No Texts - Blind 




2334 (1714) -200 (1653) -1042 (2202) 
2534 (1318 to 3750), 
p<0.001 
3376 (1951 to 4801), 
p<0.001 




21 (20) 0 (17) -8 (23) 
21 (8 to 34), 
p=0.003 
29 (13 to 45), 
P<0.001 




13 (11) -1 (8) -3 (10) 
14 (7 to 21), 
P<0.001 
16 (7 to 23), 
P<0.001 













Figure 2: Proportions Attaining the 10,000 Steps/Day Goal at Baseline, in Phase I, and 
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